Prudential Financial
AVTX icon

Prudential Financial’s Avalo Therapeutics AVTX Stock Holding History

Prudential Financial’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4
Closed -$32K – 2558
2021
Q1 		$32K Hold
4
– – ﹤0.01% 2465
2020
Q4 		$27K Hold
4
– – ﹤0.01% 2427
2020
Q3 		$23K Buy
+4
New +$30.1K ﹤0.01% 2413

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SBF
Sara-Bay Financial Sarasota, Florida $375M AUM 56.53% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Prudential Financial's AVTX Position: Q2 2021 in Review

Prudential Financial sold out of Avalo Therapeutics (AVTX) in Q2 2021, closing a stake of 4 shares — an estimated $32K sold.

Prudential Financial first reported a position in AVTX in Q3 2020 and held it in 3 quarters. The position peaked at $32K in Q1 2021. 64 funds tracked by Wall St. Rank hold AVTX as of Q2 2021.

  • Prudential Financial reported no remaining Avalo Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Prudential Financial sold 4 Avalo Therapeutics shares in Q2 2021, an estimated $32K.
  • Prudential Financial first reported a position in Avalo Therapeutics in Q3 2020 and held it in 3 quarters.
  • Prudential Financial's Avalo Therapeutics position peaked at $32K in Q1 2021.
  • 64 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2021.

Based on Prudential Financial's 13F filing for Q2 2021, filed 16 Aug 2021.